The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy?

[1]  M. Roethke,et al.  Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla , 2014, European Radiology.

[2]  Baris Turkbey,et al.  Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. , 2013, European urology.

[3]  Jan van der Meulen,et al.  Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. , 2013, Radiology.

[4]  U. Capitanio,et al.  Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. , 2013, The Journal of urology.

[5]  Xavier Leroy,et al.  Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. , 2013, Radiology.

[6]  J. Ward,et al.  PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. , 2013, The Journal of urology.

[7]  R. Molina,et al.  PCA3 in the detection and management of early prostate cancer , 2013, Tumor Biology.

[8]  R. Autorino,et al.  Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy , 2013, The Prostate.

[9]  V. Panebianco,et al.  Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate‐specific antigen levels and a previous negative biopsy , 2012, BJU international.

[10]  F. Montorsi,et al.  Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. , 2012, The Journal of urology.

[11]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[12]  Pingkun Yan,et al.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. , 2011, The Journal of urology.

[13]  M. Sotomayor,et al.  Extended sampling at first biopsy improves cancer detection rate: results of a prospective, randomized trial comparing 12 versus 18-core prostate biopsy. , 2011, The Journal of urology.

[14]  Valeria Panebianco,et al.  Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. , 2011, European urology.

[15]  B. Carey,et al.  Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. , 2011, European urology.

[16]  A. Semjonow,et al.  Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. , 2010, Clinical biochemistry.

[17]  H. Klocker,et al.  Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. , 2010, European urology.

[18]  Xavier Leroy,et al.  Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. , 2009, Urology.

[19]  D. Regge,et al.  Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. , 2008, Clinical radiology.

[20]  Jurgen J Fütterer,et al.  MR imaging in local staging of prostate cancer. , 2007, European journal of radiology.

[21]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[22]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[23]  Amit Patel,et al.  Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. , 2006, The Journal of urology.

[24]  R. Montironi,et al.  [Prostate biopsy: characteristics of the histological sample]. , 2005, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[25]  C C Schulman,et al.  Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? , 2001, The Journal of urology.

[26]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[27]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[28]  H. Cammann,et al.  Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. , 2013, Clinical chemistry.

[29]  Mark Emberton,et al.  Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.

[30]  Yair Lotan,et al.  Systematic review of complications of prostate biopsy. , 2013, European urology.